Published in Int J Cancer on November 07, 2013
Adrenomedullin and tumour microenvironment. J Transl Med (2014) 0.88
Down-regulation of malignant potential by alpha linolenic acid in human and mouse colon cancer cells. Fam Cancer (2015) 0.77
ras oncogenes in human cancer: a review. Cancer Res (1989) 22.03
Targeting hypoxia in cancer therapy. Nat Rev Cancer (2011) 7.10
The impact of O2 availability on human cancer. Nat Rev Cancer (2008) 6.84
Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science (2009) 5.31
Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science (1993) 4.76
Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun (1993) 4.32
The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ (2008) 4.31
Induction of interleukin-8 preserves the angiogenic response in HIF-1alpha-deficient colon cancer cells. Nat Med (2005) 4.27
Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study. Cancer Epidemiol Biomarkers Prev (2000) 3.05
High-resolution genome-wide mapping of HIF-binding sites by ChIP-seq. Blood (2011) 3.00
An integrative genomics approach identifies Hypoxia Inducible Factor-1 (HIF-1)-target genes that form the core response to hypoxia. Nucleic Acids Res (2009) 2.69
Regulation of vascular endothelial growth factor by the Wnt and K-ras pathways in colonic neoplasia. Cancer Res (2001) 2.47
The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma. Gut (2005) 1.73
Ras transformation requires metabolic control by 6-phosphofructo-2-kinase. Oncogene (2006) 1.68
VEGF is essential for hypoxia-inducible factor-mediated neovascularization but dispensable for endothelial sprouting. Proc Natl Acad Sci U S A (2011) 1.67
Hypoxia-inducible factor-1 (HIF-1) up-regulates adrenomedullin expression in human tumor cell lines during oxygen deprivation: a possible promotion mechanism of carcinogenesis. Mol Endocrinol (2000) 1.41
Epithelial to mesenchymal transition is impaired in colon cancer cells with microsatellite instability. Gastroenterology (2009) 1.30
Oncogenic KRAS modulates mitochondrial metabolism in human colon cancer cells by inducing HIF-1α and HIF-2α target genes. Mol Cancer (2010) 1.27
Adrenomedullin and tumour angiogenesis. Br J Cancer (2006) 1.27
The effects of adrenomedullin overexpression in breast tumor cells. J Natl Cancer Inst (2002) 1.26
Vascular endothelial growth factor and epidermal growth factor signaling pathways as therapeutic targets for colorectal cancer. Gastroenterology (2010) 1.19
Adrenomedullin is expressed in pancreatic cancer and stimulates cell proliferation and invasion in an autocrine manner via the adrenomedullin receptor, ADMR. Cancer Res (2007) 1.17
Oncogenic K-Ras turns death receptors into metastasis-promoting receptors in human and mouse colorectal cancer cells. Gastroenterology (2010) 1.16
Hypoxic regulation of vascular endothelial growth factor through the induction of phosphatidylinositol 3-kinase/Rho/ROCK and c-Myc. J Biol Chem (2006) 1.13
Oncogenic KRAS and BRAF differentially regulate hypoxia-inducible factor-1alpha and -2alpha in colon cancer. Cancer Res (2009) 1.10
Adrenomedullin antagonist suppresses in vivo growth of human pancreatic cancer cells in SCID mice by suppressing angiogenesis. Oncogene (2003) 1.08
Downregulation of c-MYC protein levels contributes to cancer cell survival under dual deficiency of oxygen and glucose. Cancer Res (2010) 1.08
Regulation of type II collagen synthesis during osteoarthritis by prolyl-4-hydroxylases: possible influence of low oxygen levels. Am J Pathol (2006) 1.07
Adrenomedullin inhibits hypoxic cell death by upregulation of Bcl-2 in endometrial cancer cells: a possible promotion mechanism for tumour growth. Oncogene (2001) 1.07
Adrenomedullin is induced by hypoxia and enhances pancreatic cancer cell invasion. Int J Cancer (2007) 1.04
The role of adrenomedullin in angiogenesis. Peptides (2005) 1.02
Angiogenic effects of adrenomedullin in ischemia and tumor growth. Circ Res (2004) 1.01
Targeting adrenomedullin receptors with systemic delivery of neutralizing antibodies inhibits tumor angiogenesis and suppresses growth of human tumor xenografts in mice. FASEB J (2009) 0.98
Hypoxia activates the K-ras proto-oncogene to stimulate angiogenesis and inhibit apoptosis in colon cancer cells. PLoS One (2010) 0.97
Expression of the adrenomedullin gene in epithelial ovarian cancer. Mol Hum Reprod (2000) 0.96
Transcriptional regulation of the CRLR gene in human microvascular endothelial cells by hypoxia. FASEB J (2003) 0.96
Tissue and plasma expression of the angiogenic peptide adrenomedullin in breast cancer. Br J Cancer (2003) 0.88
Immunohistochemical identification of adrenomedullin in human, rat, and porcine tissue. Histochem Cell Biol (1995) 0.83
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med (2004) 9.80
Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol (2008) 7.65
Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med (2006) 7.62
Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. Lancet (2009) 6.71
4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. Cancer Cell (2010) 4.48
Induction of interleukin-8 preserves the angiogenic response in HIF-1alpha-deficient colon cancer cells. Nat Med (2005) 4.27
Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol (2005) 3.83
mTORC1 in the Paneth cell niche couples intestinal stem-cell function to calorie intake. Nature (2012) 3.51
Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol (2009) 3.39
Tlx3 and Tlx1 are post-mitotic selector genes determining glutamatergic over GABAergic cell fates. Nat Neurosci (2004) 3.26
Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe (2013) 3.21
A functional variant in FCRL3, encoding Fc receptor-like 3, is associated with rheumatoid arthritis and several autoimmunities. Nat Genet (2005) 3.15
Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet (2010) 3.15
Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest (2010) 3.11
AAV2 gene therapy readministration in three adults with congenital blindness. Sci Transl Med (2012) 2.87
CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells (2009) 2.76
An integrative genomics approach identifies Hypoxia Inducible Factor-1 (HIF-1)-target genes that form the core response to hypoxia. Nucleic Acids Res (2009) 2.69
Case records of the Massachusetts General Hospital. Case 9-2014. A 34-year-old woman with increasing dyspnea. N Engl J Med (2014) 2.61
The chromosomal instability pathway in colon cancer. Gastroenterology (2010) 2.59
Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. Cancer Prev Res (Phila) (2009) 2.46
Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood (2004) 2.41
Low rate of microsatellite instability in young patients with adenomas: reassessing the Bethesda guidelines. Am J Gastroenterol (2005) 2.40
Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis. Cancer Res (2005) 2.16
Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. Cancer Res (2006) 2.15
Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc Natl Acad Sci U S A (2011) 1.97
B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Surg Pathol (2010) 1.88
Hypoxia-inducible factor-1-independent regulation of vascular endothelial growth factor by hypoxia in colon cancer. Cancer Res (2004) 1.76
Lbx1 and Tlx3 are opposing switches in determining GABAergic versus glutamatergic transmitter phenotypes. Nat Neurosci (2005) 1.73
Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors. J Natl Cancer Inst (2008) 1.71
Leptin signaling promotes the growth of mammary tumors and increases the expression of vascular endothelial growth factor (VEGF) and its receptor type two (VEGF-R2). J Biol Chem (2006) 1.70
Facilitating informed decisions regarding microsatellite instability testing among high-risk individuals diagnosed with colorectal cancer. J Clin Oncol (2010) 1.69
Prophylactic total gastrectomy for individuals with germline CDH1 mutation. Surgery (2010) 1.67
The Cables gene on chromosome 18Q regulates colon cancer progression in vivo. Cancer Biol Ther (2005) 1.65
Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer. Cancer Res (2009) 1.64
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 30-2004. A 37-year-old woman with paresthesias of the arms and legs. N Engl J Med (2004) 1.63
AAV-mediated gene therapy for choroideremia: preclinical studies in personalized models. PLoS One (2013) 1.62
LKB1--a master tumour suppressor of the small intestine and beyond. Nat Rev Cancer (2002) 1.62
Chronic sclerosing sialadenitis (Küttner tumor) is an IgG4-associated disease. Am J Surg Pathol (2010) 1.61
Somatic mutation of CDKN1B in small intestine neuroendocrine tumors. Nat Genet (2013) 1.56
HIF-1alpha and HIF-2alpha have divergent roles in colon cancer. Int J Cancer (2009) 1.54
Mechanisms of Cables 1 gene inactivation in human ovarian cancer development. Cancer Biol Ther (2007) 1.54
Subendocardial Systolic Dysfunction in Asymptomatic Normotensive Diabetic Patients. Circ J (2015) 1.52
The human visual cortex responds to gene therapy-mediated recovery of retinal function. J Clin Invest (2011) 1.52
CD95 rapidly clusters in cells of diverse origins. Cancer Biol Ther (2003) 1.50
Tissue Doppler imaging dyssynchrony parameter derived from the myocardial active wall motion improves prediction of responders for cardiac resynchronization therapy. Circ J (2012) 1.50
Sensitization to the lysosomal cell death pathway by oncogene-induced down-regulation of lysosome-associated membrane proteins 1 and 2. Cancer Res (2008) 1.50
TGF-beta receptor inactivation and mutant Kras induce intestinal neoplasms in mice via a beta-catenin-independent pathway. Gastroenterology (2009) 1.50
EZH2 codon 641 mutations are common in BCL2-rearranged germinal center B cell lymphomas. PLoS One (2011) 1.49
Multiple SNPs in intron 7 of thyrotropin receptor are associated with Graves' disease. J Clin Endocrinol Metab (2005) 1.48
HIF1A overexpression is associated with poor prognosis in a cohort of 731 colorectal cancers. Am J Pathol (2010) 1.48
BRAF and RAS oncogenes regulate Rho GTPase pathways to mediate migration and invasion properties in human colon cancer cells: a comparative study. Mol Cancer (2011) 1.47
Transmural compensation of myocardial deformation to preserve left ventricular ejection performance in chronic aortic regurgitation. J Am Soc Echocardiogr (2012) 1.46
Polycomb group suppressor of zeste 12 links heterochromatin protein 1alpha and enhancer of zeste 2. J Biol Chem (2003) 1.45
Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells. Mol Cancer Ther (2006) 1.45
Hypoxia inducible factor-1 independent pathways in tumor angiogenesis. Clin Cancer Res (2007) 1.44
The rectal tonsil: a reactive lymphoid proliferation that may mimic lymphoma. Am J Surg Pathol (2008) 1.43
Oncogenic K-ras stimulates Wnt signaling in colon cancer through inhibition of GSK-3beta. Gastroenterology (2005) 1.43
Significant improvement of left atrial and left atrial appendage function after catheter ablation for persistent atrial fibrillation. Circ J (2013) 1.41
The current status of evidence for and against postnatal oogenesis in mammals: a case of ovarian optimism versus pessimism? Biol Reprod (2008) 1.41
Oncogenic K-RAS is required to maintain changes in cytoskeletal organization, adhesion, and motility in colon cancer cells. Cancer Res (2005) 1.41
Early radiation survey of Iitate village, which was heavily contaminated by the Fukushima Daiichi accident, conducted on 28 and 29 March 2011. Health Phys (2012) 1.39
Ovarian cancer stem cell markers: prognostic and therapeutic implications. Cancer Lett (2012) 1.38
Activated forms of H-RAS and K-RAS differentially regulate membrane association of PI3K, PDK-1, and AKT and the effect of therapeutic kinase inhibitors on cell survival. Mol Cancer Ther (2005) 1.37
Leptin-signaling inhibition results in efficient anti-tumor activity in estrogen receptor positive or negative breast cancer. Breast Cancer Res (2009) 1.37
Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet Genomics (2011) 1.34
Pirh2 promotes ubiquitin-dependent degradation of the cyclin-dependent kinase inhibitor p27Kip1. Cancer Res (2007) 1.33
Proper development of relay somatic sensory neurons and D2/D4 interneurons requires homeobox genes Rnx/Tlx-3 and Tlx-1. Genes Dev (2002) 1.32
Survivin depletion preferentially reduces the survival of activated K-Ras-transformed cells. Mol Cancer Ther (2007) 1.31
Constitutive activation of Beta-catenin in uterine stroma and smooth muscle leads to the development of mesenchymal tumors in mice. Biol Reprod (2009) 1.31
Up-regulation of GPR48 induced by down-regulation of p27Kip1 enhances carcinoma cell invasiveness and metastasis. Cancer Res (2006) 1.31
Epithelial to mesenchymal transition is impaired in colon cancer cells with microsatellite instability. Gastroenterology (2009) 1.30
Validation of 3-dimensional speckle tracking imaging to quantify regional myocardial deformation. Circ Cardiovasc Imaging (2009) 1.30
Hedgehog promotes neovascularization in pancreatic cancers by regulating Ang-1 and IGF-1 expression in bone-marrow derived pro-angiogenic cells. PLoS One (2010) 1.21
Ras promotes growth by alternative splicing-mediated inactivation of the KLF6 tumor suppressor in hepatocellular carcinoma. Gastroenterology (2008) 1.21
Overexpression of cyclin D1 in pancreatic beta-cells in vivo results in islet hyperplasia without hypoglycemia. Diabetes (2005) 1.20
Transformation by oncogenic RAS sensitizes human colon cells to TRAIL-induced apoptosis by up-regulating death receptor 4 and death receptor 5 through a MEK-dependent pathway. J Biol Chem (2005) 1.20
Sharing genetic test results in Lynch syndrome: communication with close and distant relatives. Clin Gastroenterol Hepatol (2008) 1.20
Clinical characteristics of neuro-Behcet's disease in Japan: a multicenter retrospective analysis. Mod Rheumatol (2011) 1.20
TSU68 prevents liver metastasis of colon cancer xenografts by modulating the premetastatic niche. Cancer Res (2008) 1.18
Inhibition of interferon gamma signaling by the short chain fatty acid butyrate. Mol Cancer Res (2003) 1.18
Evidence for cancer stem cells in human endometrial carcinoma. Cancer Res (2009) 1.17
Prognostic histologic indicators of curatively resected hepatocellular carcinomas: a multi-institutional analysis of 425 patients with definition of a histologic prognostic index. Am J Surg Pathol (2002) 1.16
The corpus luteum: an ovarian structure with maternal instincts and suicidal tendencies. Front Biosci (2002) 1.15